Roivant Sciences Ltd.
ROIVAs of the close on Sep 25, 2026
Price
$35.80
Market cap
$25.9B
P/E (diluted TTM)
—
A per-share figure for one of the last four quarters is not shown, so no four-quarter total is given
EPS (TTM)
—
A per-share figure for one of the last four quarters is not shown, so no four-quarter total is given
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Roivant Sciences Ltd. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 6 annual periods. The latest annual period ends Mar 31, 2026. The latest insider filing shown is dated Jun 30, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| VestGen Advisors, LLC | 2026-03-31 | 37,288 | $1.1M | SEC filing |
| Aptus Capital Advisors, LLC | 2026-03-31 | 8,118 | $225K | SEC filing |
| Pictet Asset Management Holding SA | 2026-03-31 | 2,673,233 | $74M | SEC filing |
| Candriam S.C.A. | 2026-03-31 | 2,001,976 | $55.5M | SEC filing |
| ELEVATION POINT WEALTH PARTNERS, LLC | 2026-03-31 | 18,884 | $523K | SEC filing |
| RHUMBLINE ADVISERS | 2026-03-31 | 1,113,266 | $30.8M | SEC filing |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2026-03-31 | 196,195 | $5.43M | SEC filing |
| Cormorant Asset Management, LP | 2026-03-31 | 750,000 | $20.8M | SEC filing |
| Legato Capital Management LLC | 2026-03-31 | 44,856 | $1.24M | SEC filing |
| Callan Family Office, LLC | 2026-03-31 | 15,021 | $416K | SEC filing |
| Integral Health Asset Management, LLC | 2026-03-31 | 2,000,000 | $55.4M | SEC filing |
| WPG Advisers, LLC | 2026-03-31 | 45 | $1.25K | SEC filing |
| State of Tennessee, Department of Treasury | 2026-03-31 | 129,274 | $3.58M | SEC filing |
| DME Capital Management, LP | 2026-03-31 | 2,152,669 | $59.6M | SEC filing |
| Swiss National Bank | 2026-03-31 | 743,446 | $20.6M | SEC filing |
| Essential Partners LLC | 2026-03-31 | 96 | $2.66K | SEC filing |
| CITADEL ADVISORS LLC | 2026-03-31 | 2,515,998 | $69.7M | SEC filing |
| First Turn Management, LLC | 2026-03-31 | 1,190,118 | $33M | SEC filing |
| Erste Asset Management GmbH | 2026-03-31 | 214,000 | $5.65M | SEC filing |
| PFM Health Sciences, LP | 2026-03-31 | 207,446 | $5.75M | SEC filing |
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Roivant Sciences Ltd.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-02-20 · Torti Frank: Larger than 100 of the 104 other insider sales of Common Shares on file. SEC filing
- 2026-02-19 · Torti Frank: Larger than 103 of the 104 other insider sales of Common Shares on file. SEC filing
- 2025-12-31 · Sukhatme Mayukh: Larger than 101 of the 104 other insider sales of Common Shares on file. SEC filing
- 2025-12-15 · Gline Matthew: Larger than 99 of the 104 other insider sales of Common Shares on file. SEC filing
- 2025-12-12 · Ramaswamy Vivek: Larger than all 104 other insider sales of Common Shares on file. SEC filing
- 2025-12-11 · Ramaswamy Vivek: Larger than 95 of the 104 other insider sales of Common Shares on file. SEC filing
- 2025-11-19 · MANCHESTER KEITH S: Larger than 96 of the 104 other insider sales of Common Shares on file. SEC filing
- 2025-11-19 · Gold Daniel Allen: Larger than 96 of the 104 other insider sales of Common Shares on file. SEC filing
- 2025-11-19 · QVT Financial LP: Larger than 96 of the 104 other insider sales of Common Shares on file. SEC filing
- 2025-11-14 · Ramaswamy Vivek: Larger than 102 of the 104 other insider sales of Common Shares on file. SEC filing
- 2025-09-19 · Venker Eric: Larger than 94 of the 104 other insider sales of Common Shares on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-30 | MANCHESTER KEITH S · Director | Common Shares | S — Open market or private sale | −12,380 | 35.28 | SEC filing |
| 2026-06-30 | Gold Daniel Allen · Director | Common Shares | S — Open market or private sale | −12,380 | 35.28 | SEC filing |
| 2026-06-30 | MANCHESTER KEITH S · Director | Common Shares | S — Open market or private sale | −200,000 | 35.45 | SEC filing |
| 2026-06-30 | QVT Financial LP · Other | Common Shares | S — Open market or private sale | −12,380 | 35.28 | SEC filing |
| 2026-06-29 | Gold Daniel Allen · Director | Common Shares | S — Open market or private sale | −600,000 | 34.59 | SEC filing |
| 2026-06-29 | MANCHESTER KEITH S · Director | Common Shares | S — Open market or private sale | −600,000 | 34.59 | SEC filing |
| 2026-06-29 | MANCHESTER KEITH S · Director | Common Shares | S — Open market or private sale | −200,000 | 34.44 | SEC filing |
| 2026-06-29 | Gold Daniel Allen · Director | Common Shares | S — Open market or private sale | −200,000 | 34.44 | SEC filing |
Showing 8 of 11 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-26 | Sukhatme Mayukh · President & CIO | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −500,000 | SEC filing |
| 2026-06-26 | Sukhatme Mayukh · President & CIO | Common Shares | M — Exercise or conversion of derivative security | +500,000 | SEC filing |
| 2026-06-25 | Sukhatme Mayukh · President & CIO | Common Shares | M — Exercise or conversion of derivative security | +500,000 | SEC filing |
| 2026-06-25 | Sukhatme Mayukh · President & CIO | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −500,000 | SEC filing |
| 2026-06-24 | Venker Eric · President & Immunovant CEO | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −200,000 | SEC filing |
| 2026-06-24 | Venker Eric · President & Immunovant CEO | Common Shares | M — Exercise or conversion of derivative security | +200,000 | SEC filing |
| 2026-06-20 | Humes Jennifer · Chief Accounting Officer | Common Shares | F — Payment of exercise price or tax by delivering securities | −3,582 | SEC filing |
| 2026-06-20 | Pulik Richard · CFO | Common Shares | F — Payment of exercise price or tax by delivering securities | −2,129 | SEC filing |
Showing 8 of 31 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-02-09 | Sukhatme Mayukh · President & CIO | Common Shares | J — Other acquisition or disposition | −312,117 | SEC filing |
| 2025-12-31 | Sukhatme Mayukh · President & CIO | Common Shares | J — Other acquisition or disposition | −1,430,882 | SEC filing |
| 2025-12-29 | Sukhatme Mayukh · President & CIO | Common Shares | J — Other acquisition or disposition | −436,485 | SEC filing |
| 2025-12-24 | Torti Frank · President and Vant Chair | Common Shares | J — Other acquisition or disposition | −64,891 | SEC filing |
| 2025-12-17 | Sukhatme Mayukh · President & CIO | Common Shares | J — Other acquisition or disposition | −32,682 | SEC filing |
| 2025-12-15 | Gline Matthew · CEO | Common Shares | J — Other acquisition or disposition | −797,595 | SEC filing |
| 2025-12-15 | Gline Matthew · CEO | Common Shares | J — Other acquisition or disposition | −3,739 | SEC filing |
| 2025-12-15 | Ramaswamy Vivek · 10% owner | Common Shares | J — Other acquisition or disposition | −478,708 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.